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Abstract
Background: Friedewald’s formula for the estimation of LDL-C concentration is the most often used formula in
clinical practice. A recent formula by Anandaraja and colleagues for LDL-C estimation still needs to be evaluated
before it is extensively applied in diagnosis. In the present study we validated existing formulas and derived a
more accurate formula to determine LDL-C in a Serbian population.
Methods: Our study included 2053 patients with TG ≤ 4.52 mmol/L. In an initial group of 1010 patients,
Friedewald’s and Anandaraja’s formulas were compared to a direct homogenous method for LDL-C determination.
The obtained results allowed us to modify Friedewald’s formula and apply it in a second group of patients.
Results: The mean LDL-C concentrations were 3.9 ± 1.09 mmol/L, 3.63 ± 1.06 mmol/L and 3.72 ± 1.04 mmol/L
measured by a direct homogenous assay (D-LDL-C), calculated by Friedewald’s formula (F-LDL-C) and calculated by
Anandaraja’s formula (A-LDL-C), respectively in the 1010 patients. The Student’s paired t-test showed that D-LDL-C
values were significantly higher than F-LDL-C and A-LDL-C values (p < 0.001). The Passing-Bablok regression
analysis indicated good correlation between calculated and measured LDL-Cs (r > 0.89). Using lipoprotein values
from the initial group we modified Friedewald’s formula by replacing the term 2.2 with 3. The new modified
formula for LDL-C estimation (S-LDL-C) showed no statistically significant difference compared to D-LDL-C. The
absolute bias between these two methods was -0.06 ± 0.37 mmol/L with a high correlation coefficient (r = 0.96).
Conclusions: Our modified formula for LDL-C estimation appears to be more accurate than both Friedewald’s and
Anandaraja’s formulas when applied to a Serbian population.
Background
The concentration of low-density lipoprotein cholesterol
(LDL-C) is one of the strongest markers of atherosclero-
sis and predictor for assessing coronary heart disease
(CHD) risk. Strong positive association between
increased LDL-C and CHD has been well documented
[1-3]. The National Cholesterol Education Programme’s
(NCEP) Adult Treatment Panel III (ATP III) deemed
that LDL-C concentration was the primary basis for
treatment and appropriate patients’ classification in risk
categories [4] demonstrating that both accuracy and
precision of LDL-C analysis are critically important.
The reference method for LDL-C concentration mea-
surement, which combines ultracentrifugation-polianion
precipitation, it is not readily available and also
impractical in the routine laboratory [5]. A new genera-
tion of direct homogenous assays [6,7] for LDL-C deter-
mination in serum has been developed with a
satisfactory degree of accuracy but at the same time
they are expensive.
Despite some limitations, Friedewald’s formula [8] is
still the most commonly employed procedure in clinical
laboratories for the estimation of LDL-C concentration
and it has been considered acceptable for patients’ clas-
sification [4]. It is often used in developing countries,
including Serbia, due to its simplicity, convenience and
low cost. The increase in cardiovascular disease in Ser-
bian adults [9] together with the fact that risk factors
need to be established at an early stage of disease under-
line the necessity to obtain the most precise and reliable
formula for LDL-C calculation.
As already reported by other authors the homo-
geneous methods and Friedewald’s formula are not
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capable of providing identical results [10,11]. Attempts
have been made to evaluate and refine Friedewald’s ori-
ginal formula. Recently, a new formula for LDL-C esti-
mation was proposed by Anandaraja and colleagues
[12] as a substitute for Friedewald’s formula in the
Indian population.
The present study was aimed to assess the validity of
LDL-C values calculated by the Friedewald’s formula (F-
LDL-C) and those derived from Anandaraja and collea-
gues (A-LDL-C) and to compare them to values
obtained by the direct method (D-LDL-C) in order to
determine if a new formula could be applicable to a Ser-
bian population. We also examined correlations and
concentration differences obtained by the calculations
and the direct method. The results of the present study
were used to derive a new formula for calculation of
LDL-C concentration (S-LDL-C) that appears to be
more accurate than the latter two in a Serbian popula-
tion. We also examined the classification concordance
in relation to the NCEP ATP III LDL-C cut-off points
between measured LDL-C and LDL-Cs derived by the
three formulas to determine whether different calcula-
tion methods could affect patients’ classification of heart
disease risk.
Materials and methods
Participants
The first studied population (initial group) consisted of
1010 patients (51.9% male, mean age 53.7 ± 14.6 years)
who underwent routine lipid status estimation as a part
of a regular annual medical check-up. It was performed
in the “Belladonna” Clinical Chemistry Laboratory dur-
ing the whole of 2007. The second studied population
(validation group) consisted of 1043 patients (42.9%
male, mean age 54.2 ± 13 years) who were attending
regular health check-ups in the “Sava Stanojevic” Health
Centre between February and August 2008.
Blood samples were obtained in the morning after an
overnight fast from all subjects and were analysed on
the day of blood collection. Patients (45 in the initial
group and 53 in the validation group) with triglyceride
(TG) levels ≥4.52 mmol/L were excluded from further
analysis. All the study participants were free of any con-
firmed renal, hepatic or cardiovascular disease and dia-
betes mellitus.
All participants gave informed consent prior to enrol-
ment in our study that was planned according to the
ethical guidelines laid down by the Declaration of
Helsinki.
Lipid-lipoprotein analyses
Total cholesterol (TC) and TG levels were measured
enzymatically by CHOD-PAP and GPO-PAP methods
(Roche Diagnostics GmbH, Mannheim, Germany),
respectively according to the manufacturer’s specifica-
tions. High-density lipoprotein cholesterol (HDL-C) was
measured using a homogeneous assay without precipita-
tion (Roche Diagnostics GmbH, Mannheim, Germany)
[13].
A homogenous enzymatic colorimetric assay offered
by Kyowa Medex and distributed by Roche Diagnostics,
was used to measure LDL directly. The principle of
D-LDL-C determination is as follows: At pH 6.75 and
in the presence of magnesium ions, sulphated a-cyclo-
dextrin and dextran sulphate the enzymatic reaction
for cholesterol in very low-density lipoprotein (VLDL)
and chylomicrons is markedly reduced. Polyoxyethyle-
nepolyoxypropylene block polyether (POE-POP) blocks
cholesterol, especially in HDL enabling LDL-C mea-
surement by a conventional enzymatic reaction with
cholesterol oxidase, cholesterol esterase and peroxidase
(Roche Diagnostics GmbH, Mannheim, Germany)
[6,13]. Homogeneous assay has been shown to meet
current NCEP criteria for precision (CV < 4%), accu-
racy (bias < 4%) and for total analytical error (<12%)
[4,13]. The intra-assay CVs for direct LDL-C were 1.8%
at 2.0 mmol/L and 1.5% at 4.95 mmol/L and the inter-
assay CVs were 2.3% at 1.27 mmol/L and 2.1% at
2.78 mmol/L.
All analyses in both laboratories were preformed on
Roche Hitachi 911 Chemistry Analysers (Roche Diag-
nostics GmbH, Mannheim, Germany).
LDL-C concentrations were also calculated by Friede-
wald’s formula [8]: F-LDL-C (mmol/L) = TC - HDL-C -
TG/2.2 and by Anandaraja’s formula [12] A-LDL-C
(mg/dL) = 0.9*TC - 0.9*TG/5 - 28. Values in mg/dL
were calculated and then expressed in mmol/L.
The percentage difference (%ΔLDL) defined as calcu-
lated LDL-C minus D-LDL-C compared to the direct
measurement was calculated using the following for-
mula: %Δcalculated LDL-C = [(calculated LDL-C)-(D-
LDL-C)]/D-LDL-C*100. Our study evaluated the ability
of the three formulas to correctly classify subjects into
the risk categories given by NCEP ATP III using the
D-LDL-C concentrations as the true values. These cut-
off points were <2.59, 2.60 - 3.35, 3.36 - 4.12, 4.13-4.89
and > 4.90 mmol/L. Additionally, in order to improve
comparisons between the methods the samples were
stratified according to cut-off points recommended by
the NCEP ATP III for TC levels (≤4.13, 4.14 - 5.16,
5.17 - 6.20, 6.21 - 7.24 and ≥7.25 mmol/L) and for TG
levels (≤1.13, 1.14-1.69, 1.7 - 2.25, 2.26-2.82, and 2.83-
4.52 mmol/L).
Statistical analysis
Distribution of TC, TG, HDL-C, D-LDL-C, F-LDL-C, A-
LDL-C and S-LDL-C was normal according to Kolmo-
gorov-Smirnov test. Differences between values
Vujovic et al. Lipids in Health and Disease 2010, 9:27
http://www.lipidworld.com/content/9/1/27
Page 2 of 9
calculated with different formulas and from direct
method were examined by the Student’s paired t test.
The Passing-Bablok linear regression was used to evalu-
ate the degree of association between LDL-C values
from different formulas and from the direct method
[14]. Two-tailed P values less than 0.05 were considered
statistically significant. Statistic analyses were conducted
using Microsoft® Office Excel 2003.
Results
Lipoprotein concentrations and their distributions in the
initial group are given in Table 1.
The Student’s paired t-test showed that D-LDL-C
values were significantly higher than F-LDL-C and A-
LDL-C values (p < 0.001). Directly measured LDL-C
concentrations exceeded F-LDL-C and A-LDL-C con-
centrations in 82% and 65% of samples, respectively.
The mean absolute bias and the mean %ΔLDL between
calculated LDL-Cs compared to the direct method were
- 0.27 ± 0.31 mmol/L and -6.9 ± 8.8% for Friedewald’s
formula and -0.18 ± 0.51 mmol/L and -3.9 ± 14.8% for
Anandaraja’s formula.
Mean percentage differences between Friedewald’s for-
mula and direct LDL-C values (%ΔF-LDL-C) were nega-
tive in all quartiles, the lowest in the first, which
suggested that the whole distribution was shifted to
negative values (Table 1). Mean percentage differences
between Anandaraja’s formula and direct LDL-C values
(%ΔA-LDL-C) were negative in the first quartile but
positive in the third and the whole distribution was also
shifted towards negative values (Table 1).
A comparison of D-LDL-C (x) versus F-LDL-C (y) and
D-LDL-C (x) versus A-LDL-C(y) values resulted in the fol-
lowing regression equations: y = -0.17 + 0.980×, r = 0.96
and y = 0.129 + 0,971×, r = 0.89, respectively (data not
shown). In the whole initial group Friedewald’s formula
correctly classified 65% of the subjects and Anandaraja’s
formula only 55%. The same percentage of subjects (31%)
was underestimated by both formulas (data not shown).
Derivation of the modified formula
The obtained unsatisfactory results led us to re-examine
Friedewald’s formula for LDL-C estimation. Following
the procedure which led to Friedewald’s formula deriva-
tion we re-calculated factor for VLDL-C concentration
estimation. We used TC, TG, LDL-C and HDL-C con-
centration measurements in the initial group to calculate
the VLDL-C/TG ratio for a Serbian population. We first
subtracted the sum of HDL-C and LDL-C from TC for
each person. This was estimation of VLDL-C concentra-
tion for each person. Thereafter, we divided the particu-
lar TG concentration with the corresponding calculated
VLDL-C to determine the mean of the ratio. The TG/
VLDL mean ratio was 3 compared with 2.2 according to
Friedewald [8]. Therefore, the modified formula should
be stated as follows: S-LDL-C (mmol/L) = TC - TG/3 -
HDL-C. The percentage difference for our modified for-
mula (%ΔS-LDL-C) was calculated in the same way as
for Friedewald’s and Anandaraja’s formulas.
Our observation was validated in the population con-
sisting of 1043 patients. Lipoprotein concentrations
and their distributions for the validation group are
given in Table 2.
A significant difference between S-LDL-C and D-LDL-
C values was not found. The absolute bias between
these two methods was -0.06 ± 0.37 mmol/L and the
mean %ΔS-LDL-C was -0.9 ± 9.3%. A high correlation
(r = 0.96) was observed between calculated and mea-
sured values.
F- LDL-C and A-LDL-C values exhibited similar
characteristics in both study groups and were com-
pared with S-LDL-C values by calculating the percen-
tage difference (%ΔLDL). A comparison between the
values estimated by the three formulas is shown in
Figure 1. The whole distribution of %SΔLDL-C values
was almost symmetrical around the zero point indicat-
ing a similar number of negative and positive biases, all
of which were less than those obtained by Friedewald’s
and Anandaraja’s formulas.
Table 1 Basic serum lipoprotein measurements, their distributions and mean percentage differences in the initial
group (n = 1010)
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
D-LDL-C,
mmol/L
F-LDL-C,
mmol/L
ΔF-LDL-C, % A-LDL-C,
mmol/L
ΔA-LDL-C, %
Mean 5.79 1.88 1.31 3.9 3.63* -6.9 3.72* -3.9
SD 1.21 0.92 0.34 1.09 1.06 8.8 1.04 14.6
1st quartile 4.93 1.14 1 3.2 2.89 -12.1 2.99 -13.8
Median 5.7 1.68 1.2 3.8 3.55 -6.5 3.66 -6.3
3rd quartile 6.5 2.41 1.5 4.5 4.27 -1.8 4.39 5
* p < 0.001
TC: total cholesterol, TG: triglycerides, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, D-LDL-C: directly measured LDL-C, F-
LDL-C: LDL-C calculated by Friedewald’s formula, ΔF-LDL-C: mean percentage difference for Friedewald’s formula, A-LDL-C: LDL-C calculated by Anandaraja’s
formula, ΔA-LDL-C: mean percentage difference for Anandaraja’s formula.
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Subgroups defined by cut-off values (ranges) for TC,
TG and D-LDL-C values provided by NCEP ATPIII
guidelines were analysed separately (Table 3). F-LDL-C
was significantly lower (p < 0.001) compared to D-LDL-
C in all TC, TG and D-LDL-C ranges. A-LDL-C showed
no significant difference compared to D-LDL-C except
for when D-LDL-C levels were less than 3.35 mmol/L.
The optimal and closest results to D-LDL-C values were
obtained by our modified formula (S-LDL-C) (Table 3).
No differences between values were found at both the
lowest and the highest TC levels (at TG concentrations
2.26-2.82 mmol/L and at LDL-C levels <4.12 mmol/L).
Linear regression analyses demonstrated a high correla-
tion of estimated LDL-Cs with the measured D-LDL-C
(r > 0.91) in all TC, TG and D-LDL-C ranges.
The ability of the formulas to correctly classify sub-
jects at the clinical decision cut-off points in specific
subgroups is shown in Table 3. The percentages of sam-
ples correctly classified in risk categories for all formulas
decreased with increasing TC, TG and LDL-C concen-
trations except at the highest concentrations of TC and
LDL-C.
Mean %ΔLDL-C values steadily increased with
increasing TG concentrations but decreased with
increasing TC and D-LDL-C concentrations. Mean %
ΔF-LDL-C values were negative in all ranges of TC, TG
and D-LDL-C. Mean %ΔA-LDL-C values were negative
in all ranges of TC but less than the same values
obtained by Friedewald’s formula. When TG concentra-
tions were less than 1.14 mmol/L and D-LDL-C
Figure 1 Distribution of percentage differences for the Friedewald’s, Anandaraja’s and Serbian formula (Ff, Af and Sf, respectively) in
the validation group.
Table 2 Basic serum lipoprotein measurements, their distributions and mean percentage differences in the validation
group (n = 1043)
TC,
mmol/L
TG,
mmol/L
HDL-C,
mmol/L
D-LDL-C,
mmol/L
S-LDL-C,
mmol/L
ΔS-LDL-C,
%
F-LDL-C,
mmol/L
ΔF-LDL-C,
%
A-LDL-C,
mmol/L
ΔA-LDL-C,
%
Mean 6.13 1.71 1.34 4.29 4.23 -0.9 4.02* -6.1 4.09* -3.8
SD 1.31 0.87 0.36 1.2 1.16 9.3 1.15 9.9 1.14 14.1
1st
quartile
5.2 1.08 1.07 3.43 3.43 -6.3 3.22 -11.5 3.28 -12.7
Median 6.06 1.52 1.3 4.2 4.13 -2.3 3.95 -6.3 4.11 -5.3
3rd
quartile
7.02 2.16 1.55 5.1 4.98 2.7 4.78 -1.3 4.82 3.9
* p < 0.001
TC: total cholesterol, TG: triglycerides, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, D-LDL-C: directly measured LDL-C,
S-LDL-C: LDL-C calculated by new modified formula, ΔS-LDL-C: mean percentage difference for new modified formula, F-LDL-C: LDL-C calculated by Friedewald’s
formula, ΔF-LDL-C: mean percentage difference for Friedewald’s formula, A-LDL-C: LDL-C calculated by Anandaraja’s formula, ΔA-LDL-C: mean percentage
difference for Anandaraja’s formula.
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concentrations were less than 2.59 mmol/L mean %ΔA-
LDL-C values were positive (Figure 2).
Figure 2 shows that mean %ΔS-LDL-C values were
not different than ± 3% in whole TC, TG and D-LDL-C
ranges and they were much lower than mean %ΔLDL-C
values obtained from the other two formulas. This sug-
gests a better agreement with D-LDL-C than that
obtained from the two other formulas.
When TG concentrations were ≤1.13 mmol/L and
between 2.83-4.52 mmol/L our modified formula led to
the highest percentages of individuals having LDL-C
values falling within ± 10%ΔLDL-C (88% and 60%,
respectively) compared to Friedewald’s (87% and 37%,
respectively) and Anandaraja’s (60% and 32%, respec-
tively) (data not shown). In the whole validation group
%ΔLDL-C differed by more than ± 10% in 20%, 36%
and 55% of the subjects when our modified, Friedewald’s
and Anandaraja’s formulas were employed, respectively.
Discussion
Strategies for treatment of lipid abnormalities are pri-
marily based on LDL-C concentration. Therefore, LDL-
C must be accurately determined to establish a personal
CHD risk profile in order to initiate dietary adjustments,
drug therapy and to monitor their effects [4].
In the past few decades attempts have been made to
derive more accurate formulas for LDL-C calculation
than the widely used Friedewald’s formula [15-20].
Although the newer formulas offered few advantages
over the Friedewald’s, they have performed only margin-
ally better, possibly due to diversity in terms of study
populations and/or pathologies [21-23]. Some of them
included apolipoprotein concentrations, apoA-I and/or
apoB [18-20]. Anandaraja and colleagues [12] described
a new formula for LDL-C calculation in an Indian popu-
lation of 1000 patients by applying multiple linear
regression analysis and validated its accuracy in 1008
patients. In their study the mean LDL-C concentrations
measured by a precipitation method and by their for-
mula were 3.04 ± 1.04 mmol/L and 2.96 ± 0.96 mmol/L,
respectively. The mean absolute difference between both
methods was 0.1 ± 0.24 mmol/L and good correlation
was found (r = 0.97). In addition, they confirmed a
reduction in the false overestimation of LDL-C com-
pared with Friedewald’s formula. Anandaraja and collea-
gues called for the reliability of their formula to be
tested in other populations.
On the other hand, Friedewald’s formula has been
shown to be relatively reliable and recommended by the
NCEP as a routine method [5] for estimation of LDL-C
despite it having several well-established constraints. It
cannot be applied to samples containing TG levels >
4.52 mmol/L (400 mg/dL), to non-fasting samples and
to samples of patients with dysbetalipoproteinemia (Fre-
drickson Type III) [8,13]. Some authors have demon-
strated that the formula should not be used in certain
Table 3 Summary of the means ± SDs and percentages of correctly classified subjects in risk categories with regard to
the TC, TG and D-LDL-C concentrations given by NCEP ATP III in the validation group
% of subjects properly classified by
the following formulas
TC, mmol/L n D-LDL-C, mmol/L F-LDL-C, mmol/L A-LDL-C, mmol/L S-LDL-C, mmol/L Friedewald Anandaraja Modified
≤4.13 55 2.34 ± 0.44 2.13 ± 0.45** 2.12 ± 0.45** 2.28 ± 0.39 82% 84% 86%
4.14-5.16 192 3.1 ± 0.46 2.86 ± 0.43** 2.89 ± 0.41** 3.04 ± 0.39* 59% 52% 75%
5.17-6.20 310 3.88 ± 0.48 3.60 ± 0.41** 3.73 ± 0.43** 3.80 ± 0.38** 54% 42% 64%
6.21-7.24 287 4.78 ± 0.59 4.46 ± 0.43** 4.54 ± 0.42** 4.69 ± 0.39** 52% 47% 63%
≥7.25 199 5.92 ± 0.85 5.68 ± 0.77** 5.71 ± 0.70** 5.92 ± 0.77 92% 87% 94%
TG, mmol/L
≤1.13 280 3.83 ± 0.99 3.76 ± 0.97** 4.05 ± 1.04** 3.86 ± 0.98* 74% 59% 80%
1.14-1.68 324 4.32 ± 1.14 4.08 ± 1.08** 4.16 ± 1.08** 4.24 ± 1.08** 63% 59% 70%
1.69-2.25 217 4.58 ± 1.22 4.21 ± 1.21** 4.16 ± 1.21** 4.45 ± 1.20** 59% 54% 73%
2.26-2.82 97 4.64 ± 1.32 4.24 ± 1.41** 4.15 ± 1.35** 4.54 ± 1.41 55% 49% 65%
2.83-4.52 125 4.52 ± 1.32 3.98 ± 1.30** 3.85 ± 1.24** 4.4 ± 1.29* 49% 52% 67%
LDL-C, mmol/L
≤2.59 64 2.21 ± 0.30 2.07 ± 0.44** 2.23 ± 0.61 2.27 ± 0.39 91% 77% 81%
2.6-3.35 181 3.03 ± 0.21 2.90 ± 0.37** 3.00 ± 0.50 3.07 ± 0.35 61% 55% 71%
3.36-4.12 262 3.77 ± 0.22 3.60 ± 0.45** 3.71 ± 0.57* 3.79 ± 0.44 61% 45% 69%
4.13-4.89 213 4.50 ± 0.23 4.15 ± 0.42** 4.25 ± 0.56** 4.37 ± 0.39** 52% 49% 63%
≥4.9 323 5.67 ± 0.74 5.29 ± 0.81** 5.28 ± 0.81** 5.23 ± 0.81** 67% 66% 80%
* p < 0.05, ** p < 0.001
LDL-C: low-density lipoprotein cholesterol, D-LDL-C: directly measured LDL-C, F-LDL-C: LDL-C calculated by Friedewald’s formula, A-LDL-C: LDL-C calculated by
Anandaraja’s formula, S-LDL-C: LDL-C calculated by the new modified formula.
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Figure 2 Mean percentage differences for Friedewald’s (Ff), Anandaraja’s (Af) and our modified (Sf) formula according to TC (A), TG
(B) and LDL-C (C) cut-off values proposed by NCEP ATP III in the validation group.
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groups of patients with diabetes, liver and renal dysfunc-
tion even with TG levels < 4.52 mmol/L [17,22,23]. The
formula relies on the accuracy of the TC, TG and HDL-
C assays and also on an additional mathematical term
that is used to estimate the VLDL-C concentration. It
assumes a fixed relationship between TC, TG, and
HDL-C in fasting serum providing the TG/cholesterol
ratio in the VLDL is constant and the assumption that
TG is only present as VLDL. As well, the homogenous
Roche method we have used has some limitations
[6] although it has been reviewed by Nauck et al [13] to
be precise and acceptably accurate. It gives an improve-
ment in the measurement of LDL-C in samples with
high TG and may assist better in classification of
patients at risk categories for cardiovascular diseases
than Friedewald’s equation.
Anandaraja’s team did not propose any limitations to
their formula. Comparing the mean value of the direct
LDL-C obtained in the first 1000 patients and that in
the validation group of 1008 patients it seemed they did
not exclude samples with high TG levels [12]. In a study
of over 10000 Brazilian patients Gasko and colleagues
[24] supported Anandaraja’s formula. The mean LDL-C
level measured by a direct method and that estimated
by the new formula were similar to the Indian popula-
tion (2.99 ± 0.57 mmol/L and 2.97 ± 0.59 mmol/L,
respectively). The correlation coefficient between both
methods was r = 0.97. Anandaraja’s formula was also
checked in 230 Greek patients (118 had metabolic syn-
drome and 112 were healthy) by Gazi and Elisaf
[25]. Friedewald’s and Anandaraja’s formulas gave simi-
lar results in the examined Greek population. The latter
was approved for use in their laboratories.
In our study we investigated if Anandaraja’s formula
could be applied in the Serbian population by compar-
ing the value obtained with that of the homogenous
direct method for LDL-C determination. This is the first
study of its kind where the reliability and accuracy of
Friedewald’s formula were tested in the Serbian popula-
tion. In our initial group LDL-C values from the direct
measurement and from Anandaraja’s formula were both
higher than the values in Indian, Brazilian and Greek
populations by almost 1 mmol/L [12,24,25]. The A-
LDL-C concentration was significantly lower than the
D-LDL-C concentration (Table 1). The correlation coef-
ficient between methods was good (r = 0.89) but lower
than previously published (r = 0.97) [12,24].
To the best of our knowledge only Paz and colleagues
[26] have performed a detailed systematic analysis of the
reliability of Anandaraja’s formula. They tested the new
formula in schizophrenic patients treated with antipsy-
chotic drugs. Their results demonstrated that LDL-
CAnandaraja concentrations were underestimated or over-
estimated compared to LDL-CElectrophoresis and depended
on the HDL-C concentrations. They found a higher
correlation and a lower estimation error between LDL-
CElectrophoresis and LDL-CFriedewald than LDL-CElectrophor-
esis and LDL-CAnandaraja. For that reason improved accu-
racy of Anandaraja’s formula over Friedewald’s formula
was not claimed. Data from our study are in agreement
with Paz and colleagues. We employed two apparently
healthy populations from two different Serbian cities in
which all analyses were completed with the same type
of reagents on the same class of autoanalyser. In both
populations the results were very similar and did not
support Anandaraja’s formula (Table 1 and 2). The per-
centages of patients properly classified in NCEP’s risk
categories and the percentage of patients that fell in
the ± 10%ΔLDL-C group were smaller when compared
to Friedewald’s formula in all ranges of TC, TG and
LDL-C (Table 3).
Figure 1 shows that %ΔLDL-C distribution for Ana-
ndaraja’s formula was overrached and dismounted com-
pared to Friedewald’s. Our findings concerning
Friedewald’s formula are consistent with other published
studies. As reported earlier [10,27,28], we found that
calculated LDL-C values derived from Friedewald’s for-
mula often underestimate directly measured LDL-C
concentrations. Tighe and colleagues [10] found good
correlation between LDL-C calculated by Friedewald’s
formula and directly measured LDL-C (r = 0.90). Only
48.1% of samples in Tighe’s study showed similar results
compared to 63% in our validation group.
Jun and co-workers [27] revealed that F-LDL-C dif-
fered significantly from D-LDL-C over the concentration
ranges of both TC and TG. They found that the mean %
ΔLDL was -9.1% and assumed that this difference was
critical for the evaluation of patients with hyperlipide-
mia. Their study demonstrated that higher TG resulted
in a greater %ΔF-LDL-C and increased TC was asso-
ciated with decreased %ΔF-LDL-C, which was also con-
firmed in our current study.
It would appear that calculated LDL-Cs by both Frie-
dewald’s and Anandaraja’s formulas give unsatisfactory
results compared to the direct homogenous method. It
seems that the only advantage of Anandaraja’s formula
is the requirement of the concentration of only 2 vari-
ables (TC and TG) that reduces the analytical error.
Our study in a Serbian population revealed that the
HDL-C concentration should not be omitted from the
formula, in agreement with Paz and colleagues [26].
In the course of the present study to investigate the
reliability of Friedewald’s and Anandaraja’s formulas we
derived a new modified formula. It resembles Friede-
wald’s and it is based on the original study [8]. Simple
division of plasma TG by 2.2 for mmol/L or 5 for mg/
dL does not give a very accurate estimation of VLDL-C
even in a healthy population. Some authors have
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proposed alternative calculations including TG/4, TG/
4.5, TG/5, TG/5.5, TG/6, TG/7 and TG/8 (mg/dL)
[15,16]. Nakanishi and colleagues [16] demonstrated
that the TG/5 formula correlated well with measured
LDL-C and had the smallest mean difference between
estimated and measured LDL-C in middle-aged Japa-
nese men. Gonzales-Estrada [29] concluded that the
DeLong (TG/2.7 mmol/L or TG/6.17 mg/dL) calcula-
tion [15] was more convenient than the original Friede-
wald’s formula for most cases, despite a high error. On
the contrary, according to some authors DeLong’s for-
mula did not improve LDL-C determination [21,23].
In our initial population we calculated that to deter-
mine cholesterol in VLDL, TG should be divided by
3 (mmol/L) or 6.85 (mg/dL). Our modified formula was
tested and its accuracy was validated in our second
population. S-LDL-C showed no statistically significant
difference compared to D-LDL-C in the validation
group, despite the fact that there was still an underesti-
mation. No significant difference between these two
mean values was found in situations of TC < 4.13
mmol/L and TC > 7.24 mmol/L, TG 2.26 - 2.82 mmol/
L and LDL-C < 4.12 mmol/L. The mean %ΔS-LDL-C
was -0.9%, the smallest among these three calculations
(Table 2). Our modified formula exhibited the lowest
mean %ΔLDL-C in all ranges of TG, TC and D-LDL-C
compared to Friedewald’s and Anandaraja’s formulas
(Figure 2). As for the accuracy of the calculation
method, the proportion of samples falling within a fairly
broad ± 10%ΔLDL-C range was the highest. Our results
indicate that LDL-C concentrations derived from the
modified formula provide more accurate results com-
pared to those derived from Friedewald’s and Anandara-
ja’s formulas for Serbian population.
According NCEP-ATP III guidelines, LDL-C concen-
trations < 3.36 mmol/L are considered desirable while
those > 4.14 mmol/L are considered high. Medication
should be administered to subjects falling into the latter
group [4]. Our study demonstrated that 45%, 45% and
26% of samples from Friedewald’s, Anandaraja’s and our
modified formula, respectively underestimated the diag-
nostic LDL-C level of 4.14 mmol/L and were classified
one cut-off point below that indicated for therapy (data
not shown).
In conclusion, regarding patients’ convenience, finan-
cial reasons and precision and accuracy we propose that
our new modified formula should be used instead of
Friedewald’s formula for the estimation of LDL-C con-
centration in the Serbian population. We appeal to all
laboratories principally in Serbia and in neighbouring
countries with similar living conditions and habits to
test our modified formula before its eventual
implementation.
List of abbreviations
CHD: coronary heart disease; NCEP: National Choles-
terol Education Program; ATP III: Adult Treatment
Panel III; F-LDL-C: LDL-C value calculated by Friede-
wald’s formula; A-LDL-C: LDL-C value calculated by
Anandaraja’s formula; S-LDL-C: LDL-C value calculated
by our new modified formula; %ΔLDL: percentage
difference.
Acknowledgements
This work was financially supported by a grant from the Ministry of Science
and Environmental Protection, Republic of Serbia (project number 145036B).
The study was also supported by COST B35 Action. We want to thank our
colleague Dr. David R. Jones for help in editing the manuscript.
Author details
1Institute of Medical Biochemistry, Faculty of Pharmacy, Belgrade, Serbia.
2“Belladonna” Clinical Chemistry Laboratory, Zemun, Belgrade, Serbia.
3Belgrade Clinical Centre, Laboratory Department, Belgrade, Serbia. 4“Sava
Stanojevic” Health Centre, Trstenik, Serbia.
Authors’ contributions
AV wrote the manuscript and statistically analyzed data. JKS participated in
the study design, statistically analysed data and critically revised the
manuscript, SS carried out all aspects of the study design, statistically
analysed data and critically revised the manuscript, NB performed
experimental work and collected samples, MV performed experimental work
and collected samples, JM performed experimental work and collected
samples, VSK critically revised the manuscript, AZ critically revised the
manuscript, DP collected samples. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 January 2010 Accepted: 10 March 2010
Published: 10 March 2010
References
1. Scandinavian Simvastatin Survival Study Group: Randomised trial of
cholesterol lowering in 4444 patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group: Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad range
of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
3. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic
atherosclerosis. J Am Med Assoc 2001, 285:2481-2485.
4. Executive summary of the third report of the National Cholesterol
Education Programme (NCEP) Expert panel on detection, evaluation,
and treatment of high blood cholesterol in adults (Adult Treatment
Panel III). J Am Med Assoc 2001, 285:2486-2497.
5. Bachorick PS, Ross JW: For the National Cholesterol Education Program
Working Group on Lipoprotein Measurements. National Cholesterol
Education Program recommendations for measurement of low-density
lipoprotein cholesterol: executive summary. Clin Chem 1995,
41:1414-1420.
6. Bairaktari ET, Seferiadis KI, Elisaf MS: Evaluation of Methods for the
Measurementof Low-Density Lipoprotein Cholesterol. J Cardiovasc
Pharmacol Therapeut 2005, 10:45-54.
7. Nauck M, Warnick GR, Rifai N: Methods for Measurement of LDL-
Cholesterol: A Critical Assessment of Direct Measurement by
Homogeneous Assays versus Calculation. Clin Chem 2002, 48:236-254.
8. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
Vujovic et al. Lipids in Health and Disease 2010, 9:27
http://www.lipidworld.com/content/9/1/27
Page 8 of 9
9. Vukomirovic D: Causes of deaths. Statistical Yearbook of Serbia 2005
Statistical Office of the Republic of Serbia, Belgrade, Serbia 2005, 90, (In
Serbian).
10. Tighe DA, Ockene IS, Reed G, Nicolosi R: Calculated low density
lipoprotein cholesterol levels frequently underestimate directly
measured low density lipoprotein cholesterol determinations in patients
with serum triglyceride levels or <=4.52 mmol/l: an analysis comparing
the LipiDirect® magnetic LDL assay with the Friedewald calculation. Clin
Chim Acta 2006, 365:236-242.
11. Esteban-Salan M, Guimon-Bardesi A, de La Viuda-Unzueta JM, Azcarate-
Ania MN, Pascual-Usandizaga P, Amoroto-Del-Rio E: Analytical and clinical
evaluation of two homogeneous assays for LDL-cholesterol in
hyperlipidemic patients. Clin Chem 2000, 46:1121-1131.
12. Anandaraja S, Narang R, Godeswar R, Laksmy R, Talwar KK: Low-density
lipoprotein cholesterol estimation by a new formula in Indian
population. Int J Cardiol 2005, 102:117-120.
13. Nauck M, Graziani MS, Bruton D, Cobbaert C, Cole TG, Lefevre F, Riesen W,
Bachorik PS, Rifai N: Analytical and Clinical Performance of a Detergent-
based Homogeneous LDL-Cholesterol Assay: A Multicenter Evaluation.
Clin Chem 2000, 46:506-514.
14. Passing H, Bablok W: A new biometrical procedure for testing the
equality of measurements from two different analytical methods.
Application of linear regression procedures for method comparison
studies in Clinical Chemistry, Part I. J Clin Chem Clin Biochem 1983,
21:709-720.
15. DeLong DM, DeLong ER, Wood PD, Lippel K, Rifkind BM: A comparison of
methods for the estimation of plasma low- and very low-density
lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study.
J Am Med Assoc 1986, 256:2372-2377.
16. Nakanishi N, Matsuo Y, Yoneda H, Nakamura K, Suzuki K, Tatara K: Validity
of the Conventional Indirect Methods Including Friedewald Method for
Determining Serum Low-Density Lipoprotein Cholesterol Level:
Comparison with the Direct Homogeneous Enzymatic Analysis. J Occup
Health 2002, 42:130-137.
17. Bairaktari ET, Tzallas C, Kalientzidou M, Tselepis AD, Siamopoulos KC,
Seferiadis KI, Elisaf M: Evaluation of alternative calculation methods for
determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis
patients. Clin Biochem 2004, 37:937-940.
18. Planella T, Cortes M, Martinez-Bru C, Gonzalez-Sastre F, Ordonez-Llanos J:
Calculation of LDL-cholesterol by using apolipoprotein B for
classification of nonchylomicronemic dyslipemia. Clin Chem 1997,
43:808-815.
19. Hattori Y, Suzuki M, Tsushima M, Yoshida M, Tokunaga Y, Wang Y, Zhao D,
Takeuchi M, Hara Y, Ryomoto KI, Ikebuchi M, Kishioka H, Mannami T, Baba S,
Harano Y: Development of approximate formula for LDL-chol, LDL-apo B
and LDL-chol:LDL-apo B as indices of hyperapobetalipoproteinemia and
small dense LDL. Atherosclerosis 1998, 138:289-299.
20. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High
apolipoprotein B, low apolipoprotein A-I, and improvement in the
prediction of fatal myocardial infarction (AMORIS study): a prospective
study. Lancet 2001, 358:2026-2033.
21. Warnick GR, Knopp RH, Fitzpatrick V, Branson L: Estimating Low-Density
Lipoprotein Cholesterol by the Friedewald Equation Is Adequate for
Classifying Patients on the Basis of Nationally Recommended Cutpoints.
Clin Chem 1990, 36:15-19.
22. Rubies-Prat J, Reverter JL, Senti M, Pedro-Botet I, Salinas I, Lucas A,
Nogues X, Sanmartì A: Calculated low-density lipoprotein cholesterol
should not be used form management of lipoprotein abnormalities in
patients with diabetes mellitus. Diabetes Care 1993, 16:1081-1086.
23. Matas C, Cabre M, La Ville A, Prats E, Joven J, Turner PR, Masana L,
Campus J: Limitations of the Friedewald Formula for Estimating Low-
Density Lipoprotein Cholesterol in Alcoholics with Liver Disease. Clin
Chem 1994, 40:404-406.
24. Gasko R: Low-density lipoprotein cholesterol estimation by the
Anandaraja’s formula - confirmation. Lipids in Health and Disease 2006,
5:18.
25. Gazi IF, Elisaf M: LDL-cholesterol calculation formulas in patients with or
without the metabolic syndrome. Int J of Cardiol 2007, 119:414-415.
26. Paz E, Hermida J, Bouzas L, Brenlla J, Tutor JC: LDL cholesterol estimation
using the Anandaraja’s and Friedewald’s formulas in schizophrenic
patients treated with antipsychotic drugs. Clin Biochem 2008,
41:1002-1007.
27. Jun KR, Park H, Chun S, Park H, Min WK: Effects of total cholesterol and
triglyceride on the percentage difference between the low-density
lipoprotein cholesterol concentration measured directly and calculated
using the Friedewald formula. Clin Chem Lab Med 2008, 46(Supp
3):371-375.
28. Marniemi J, Maki J, Maatela J, Jarvisalo J, Impivaara O: Poor applicability of
the Friedewald formula in the assessment of serum LDL cholesterol for
clinical purposes. Clin Biochem 1995, 28:285-289.
29. Gonzalez Estrada M, Rodríguez Ferrer CR, Astarloa IR, Lahera EM: Use of
Serum CholesteroliTriglyceride Ratio to Discern for Which Individuals the
Friedewald Formula Can Be Used Confidently. Clin Chem 1990,
36:1673-1675.
doi:10.1186/1476-511X-9-27
Cite this article as: Vujovic et al.: Evaluation of different formulas for
LDL-C calculation. Lipids in Health and Disease 2010 9:27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vujovic et al. Lipids in Health and Disease 2010, 9:27
http://www.lipidworld.com/content/9/1/27
Page 9 of 9
